Survival has been considered traditionally as the gold-standard endpoint for cancer clinical trials. This tradition is congruent with the historical requirement of the US Food and Drug Administration (FDA) that improvement in either survival or meaningful clinical benefit, such as amelioration of major symptoms, is needed to justify marketing approval of a new drug. However, the high failure rate of drugs in the pipeline, notably cancer drugs, led to a perception by many stakeholders that the system of drug approval was too strict, impeding the successful approval of active agents. Urgency in developing drugs to combat the AIDS epidemic provided a strong impetus to consider shorter-term endpoints as surrogates for survival (1, 2) . This evolving political climate led ultimately to relaxation of the criteria for drug approval by the FDA, notably the initiation of accelerated approval "for drugs that are intended to treat serious or life-threatening conditions … based on an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit" (3). Surrogate endpoints now frequently considered in oncology are disease-free survival (DFS) and progression-free survival (PFS). Likewise, the European Medicines Agency now formally recognizes both DFS and PFS as "acceptable" endpoints, although overall survival (OS) must be reported as a secondary endpoint (4). These trends have led to the design and completion of an increasing number of cancer trials that use actuarial endpoints that occur considerably sooner than death rather than tumor response or OS as endpoints. Such endpoints include DFS, PFS, and a number of other variants. This in turn has led to many studies over the past decade investigating the suitability of these endpoints.
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Two articles in this issue of the Journal by Oba et al. and Paoletti et al. are exemplars of this area of research (5, 6) . These studies examine the use of DFS as a surrogate endpoint for OS in adjuvant trials of gastric cancer and PFS as a surrogate for OS in trials of advanced or recurrent gastric cancer. Both studies involve meta-analysis of completed randomized trials in which results are available comparing treatments with respect to both the surrogate endpoint under investigation and OS. The authors conclude from these studies that DFS is an appropriate surrogate for OS in studies of gastric cancer in the adjuvant setting but that PFS is not an appropriate endpoint for studies of advanced or recurrent gastric cancer.
A number of methods are available for evaluating the validity of surrogate endpoints. Both Oba et al. and Paoletti et al. (5, 6) have pursued a strategy that has been used frequently in recent years. The fundamental framework for this strategy is to examine historical trials and to evaluate the congruence of the conclusions regarding the effects of the treatments. In essence, this involves correlating the effect size of the treatment on OS with the corresponding effect size on the surrogate endpoint. Strong congruence of the effect sizes of the two endpoints supports the premise that the surrogate endpoint is a valid replacement for OS, although the strength of the statistical measure can be strongly dependent on the range of effect sizes observed in the historical studies.
The meta-analysis of Oba et al. demonstrates impressively close concordance of the effects of treatment on OS and DFS from 14 historical adjuvant trials of gastric cancer (5) . These results exemplify the fact that in the adjuvant setting disease recurrence is a pivotal event in the natural history of the disease for most solid tumors. Recurrence predicts strongly ultimate death from disease. Indeed the rank correlation between DFS and OS was observed to be a remarkably high 0.97. Given these facts, the evidence is indeed strong that trials that use DFS as the primary endpoint will provide conclusions that predict the effect on OS reliably. In a commentary on a similar debate about the use of DFS as an endpoint in colorectal cancer trials, Grothey speculated that in the emerging landscape of biologically targeted agents the reliability of DFS may be compromised (7) . However, this concern is largely speculative at present, and without evidence to the contrary, it is reasonable to believe that relapse is a strong early indicator of the ultimate failure to control the disease and cure the patient regardless of the nature of the systemic treatment under consideration.
The issue of the use of PFS in the advanced disease setting addressed by Paoletti et al. (6) is more ambiguous. The authors also observe strong concordance between the effect sizes of the treatments on OS and on the surrogate endpoint. However, the strength of this association, an R 2 value of 61%, is considerably lower than the R 2 of 96% for DFS in the study by Ota et al (5) . There are a number of reasons why, say, an improvement due to treatment on OS may be compromised when viewed through the prism of PFS. Progression in patients with existing observable disease burden is a more nebulous concept than the reappearance of disease in a patient who is apparently disease-free, requiring an arbitrary definition of tumor growth that inevitably involves more measurement error than the determination that disease has recurred in a patient who was disease-free. Also, the impact of postprogression treatments could dilute or even eliminate an apparent improvement in tumor control demonstrated in a trial. Examples of this possibility are described by Booth and Eisenhauer (8) . Although such influences have the potential to also compromise the interpretations of adjuvant trials using DFS, there is essentially no evidence of this in the study by Oba et al.
Do the results from Paoletti et al. (6) justify PFS as an endpoint for trials of advanced gastric cancer? The authors conclude that the answer is no, but it is not entirely clear how they reached this conclusion. They quote a number of statistics that characterize in various ways the concordance of PFS and OS results, in addition to R 2 . However, these measures are all ultimately descriptive and do not lend themselves to a definitive criterion for determining whether the use of the surrogate endpoint is justified. There is an implicit comparison with a previous study evaluating PFS for use in advanced trials of colorectal cancer involving several of the same authors, which concluded that PFS is a valid surrogate (9) . However the rank correlation of PFS and OS is actually higher in the gastric cancer study, 0.85 compared with 0.82, and the R 2 value of 0.61 correlating the effect sizes is only modestly lower than the 0.74 observed in the colorectal study. [Note that this latter estimate involved the exclusion of an "outlier" study.] So what is different about gastric cancer that would justify the disparate recommendations?
The style of presentation of these studies is heavily focused on the various statistical comparisons but it is light on the aspects of the clinical setting that might help to influence a conclusion that is ultimately a judgment call. In studies of this nature, there is no accepted statistical test or definitive statistical standard that a surrogate endpoint must meet to justify its use in future studies. Consequently the statistical evidence must be embellished with knowledge about the clinical context for which hard statistical evidence may be unavailable or more difficult to collect. How valuable is delay of progression to the quality of life of patients generally? How much variation exists in techniques used to measure progression, and how much confidence do we have in the available methods? To what extent might the use of PFS speed the process of evaluating new treatments without undermining the credibility of the evaluation process? Decision making in this context cannot be relegated to purely statistical comparisons without substantive judgment of this nature. 
